GLP-1 receptor agonists mimic these effects, promoting satiety (feeling full), suppressing glucagon (a blood sugar-raising hormone), and enhancing insulin sensitivity
These data are useful not as therapeutic endpoints, but as a way of examining how tri-agonist signaling may affect tissue-level energy partitioning under experimental conditions [2][3][5]
This leads to feelings of fullness and decreased appetite
Telehealth companies high risk when making claims and branding compounded drugs
More recent research looking at longer treatment periods shows that weight loss may continue over time, especially at higher doses: Weight loss in later trials (68 weeks, Phase 3) These later results suggest that with continued treatment, some people may lose even more weight than what was seen in earlier trials
Follow the dosage instructions on the label